Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;158(4):1794-1795.
doi: 10.1016/j.chest.2020.05.574.

Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic

Steven C Springmeyer  1 , James Jett  2 , Krish Bhadra  3 , Fayez Kheir  4 , Adnan Majid  4
Affiliations
Comment

Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic

Steven C Springmeyer et al. Chest. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pretest and posttest distributions using the integrated classifier in selected lung nodules. Shown is the probability of cancer (pCA) pretest and posttest values from two studies. A, from the clinical validation study with 8-30 mm nodules with a physician and SPN pCA pretest of ≤50% along with no cancer history within 5 years. B, data from the registry trial with the same selection criteria. The dashed lines within the plots indicate the median values, and the dotted line indicates the 5% pCA level. The corresponding numbers and percentages that fall below the 5% pCA line are shown at the bottom of the figure.
See this image and copyright information in PMC

Comment on

References

    1. Mazzone P.J., Gould M.K., Arenberg D.A., et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158(1):406–415. - PMC - PubMed
    1. Massion P.P., Healey G.F., Peek L.J., et al. Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer. J Thorac Oncol. 2017;12(3):578–584. - PMC - PubMed
    1. Healey G.F., Macdonald I.K., Reynolds C., et al. Tumor-associated autoantibodies: re-optimization of early CDT-lung diagnostic performance and its application to indeterminate pulmonary nodules. J Cancer Ther. 2017;8:506–517.
    1. Silvestri G.A., Tanner N.T., Kearney P., et al. Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (pulmonary nodule plasma proteomic classifier) trial. Chest. 2018;154(3):491–500. - PMC - PubMed
    1. Pritchett M., Sigal B.W., Bowling M.R., et al. First look at the distribution of risk of malignancy pre and post-test using a blood-based biomarker in patients with pulmonary nodules in a real-world observational study. AJRCCM. 2020;201:A4465.